A STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF BILASTINE, DESLORATADINE, AND LEVOCETIRIZINE ON PSYCHOMOTOR PERFORMANCE AND SALIVARY FLOW IN PATIENTS WITH CHRONIC URTICARIA ATTENDING DERMATOLOGY OUTPATIENT DEPARTMENT AT A TERTIARY CARE CENTER
DOI:
https://doi.org/10.22159/ajpcr.2025v18i3.53701Keywords:
Bilastine,, Desloratadine, Levocetirizine,, Salivary flow, Psychomotor performanceAbstract
Objectives: Antihistamines are the most used systemically delivered medications for skin conditions that can inhibit cholinergic (muscarinic) receptors and block central H1 receptors leading to effects such as dryness of mouth and sedation, respectively. Bilastine, desloratadine, and levocetirizine are second-generation antihistamines which have variable effects on dryness of mouth and sedation; hence, the objective of this study is to evaluate any differences in these effects in chronic urticaria patients prescribed the above-mentioned antihistamine drugs.
Methods: Subjects with chronic urticaria who were prescribed any of the three antihistamines by the dermatologist were enrolled. Baseline readings of salivary flow by cotton ball method and psychometric performances by digit letter substitution test (DLST), six letter cancellation test (SLCT), card sorting test, and Visual Analog Scale (VAS) for dryness of mouth and sedation measured before administration of prescribed antihistaminic drug and compared with readings taken of the same tests after 7 days of antihistaminic drug administration.
Results: A total of 36 subjects were enrolled median age of 38.5 years (range 18–57 years) and 55% (20/36) were males. Reduction in the mean salivary flow and the psychomotor performance were not significantly different between the three drug groups, although there were reductions in the three groups in the outcome measures salivary flow and psychomotor performance tests including DLST and SLCT when compared to baseline.
Conclusion: The three drugs are similar with respect to their adverse effect profile in terms of causing dryness of mouth and impairment of psychomotor performance.
Downloads
References
Greaves MW. Antihistamines in dermatology. Skin Pharmacol Physiol. 2005 Oct 1;18(5):220-9. doi: 10.1159/000086667, PMID: 16015020
Gengo FM, Dabronzo J, Yurchak A, Love S, Miller JK. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther. 1987;42(3):265-72. doi: 10.1038/clpt.1987.145, PMID: 2887328
Qidwai JC, Watson GS, Weiler JM. Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep. 2002 May;2(3):216-22. doi: 10.1007/s11882-002-0022-1, PMID: 11918863
Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 2):S622-7. doi: 10.1067/ mai.2000.106153, PMID: 10856168
Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol. 1995;116(1):1649-55. doi: 10.1111/j.1476-5381.1995. tb16386.x, PMID: 8564232
Danjou P, Molinier P, Berlin I, Patat A, Rosenzweig P, Morselli PL. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol. 1992;34(4):328-31. doi: 10.1111/j.1365-2125.1992.tb05638.x, PMID: 1360807
Patat A, Perault MC, Vandel B, Ulliac N, Zieleniuk I, Rosenzweig P. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol. 1995;39(1):31-8. doi: 10.1111/j.1365- 2125.1995.tb04406.x, PMID: 7756096
Riedel WJ, Van Veggel, O’Hanlon JF. Cetrizine 10 and 20 mg impair psychomotor performance. Clin Exp Allergy. 1990;20(Suppl 1):97.
Pechardre JC, Beudin P, Eschalier A, Trolese JF, Rihoux. A comparison of central and peripheral effects of cetirizine and loratadine. J Int Med Res. 1991;19:289-95.
Danjou PH, Dunmore C, Curson VH, Rosenzweig P, Hindmarch I, Morselli PL. A double-blind placebo control of study of the psychometric effect of the SL. 85.0324 a new H1 antagonist drug compared to terfinadine and tripolidine in healthy subjects. Eur J Pharmacol. 1990;183(2):534. doi: 10.1016/0014-2999(90)93439-W
Published
How to Cite
Issue
Section
Copyright (c) 2025 Imran Khan, Padmaja Mekala, Asiya Begum, Usharani Pingali, Sumedh G K

This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.